Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
54.46 x 1 57.56 x 1
Post-market by (Cboe BZX)
56.17 -1.70 (-2.94%) 01/10/25 [NASDAQ]
54.46 x 1 57.56 x 1
Post-market 56.17 unch (unch) 16:20 ET
Quote Overview for Fri, Jan 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
55.69
Day High
56.99
Open 56.21
Previous Close 57.87 57.87
Volume 591,000 591,000
Avg Vol 554,215 554,215
Stochastic %K 54.77% 54.77%
Weighted Alpha +17.85 +17.85
5-Day Change -3.90 (-6.49%) -3.90 (-6.49%)
52-Week Range 35.17 - 68.58 35.17 - 68.58
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,452,040
  • Shares Outstanding, K 61,457
  • Annual Sales, $ 77,430 K
  • Annual Income, $ -184,680 K
  • EBIT $ -266 M
  • EBITDA $ -250 M
  • 60-Month Beta 2.16
  • Price/Sales 31.06
  • Price/Cash Flow N/A
  • Price/Book 315.45

Options Overview Details

View History
  • Implied Volatility 48.67% ( +0.41%)
  • Historical Volatility 39.70%
  • IV Percentile 29%
  • IV Rank 21.58%
  • IV High 82.47% on 08/05/24
  • IV Low 39.36% on 11/19/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 513
  • Volume Avg (30-Day) 330
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 7,473
  • Open Int (30-Day) 8,223

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.73
  • Number of Estimates 10
  • High Estimate -0.41
  • Low Estimate -1.03
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -4.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.39 +5.21%
on 12/18/24
Period Open: 57.74
60.52 -7.19%
on 01/02/25
-1.57 (-2.72%)
since 12/10/24
3-Month
47.61 +17.98%
on 10/31/24
Period Open: 47.97
68.58 -18.10%
on 11/11/24
+8.20 (+17.09%)
since 10/10/24
52-Week
35.17 +59.71%
on 05/29/24
Period Open: 42.51
68.58 -18.10%
on 11/11/24
+13.66 (+32.13%)
since 01/10/24

Most Recent Stories

More News
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

RYTM : 56.17 (-2.94%)
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

RYTM : 56.17 (-2.94%)
Rhythm Pharmaceuticals Receives Expanded MHRA Marketing Authorization for IMCIVREE® to Treat Obesity in Children as Young as 2 Years with Rare Genetic Conditions

Rhythm Pharmaceuticals announces expanded marketing authorization for IMCIVREE® to treat obesity in patients with specific genetic conditions.Quiver AI SummaryRhythm Pharmaceuticals, Inc. announced that...

RYTM : 56.17 (-2.94%)
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency...

RYTM : 56.17 (-2.94%)
Rhythm Pharmaceuticals Announces Positive Weight Reduction Results in Pediatric Patients Treated with Setmelanotide in Early-Access Program and Plans New Substudy for Congenital Hypothalamic Obesity

Four pediatric patients using setmelanotide therapy showed significant weight loss in a French early-access program, prompting further study.Quiver AI SummaryRhythm Pharmaceuticals announced promising...

RYTM : 56.17 (-2.94%)
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

RYTM : 56.17 (-2.94%)
Rhythm Pharmaceuticals Publishes Positive Phase 3 VENTURE Trial Results for Setmelanotide in Young Children with Rare Genetic Obesity Conditions

Rhythm Pharmaceuticals reports Phase 3 trial results showing setmelanotide reduces hunger and weight in young children with severe obesity.Quiver AI SummaryRhythm Pharmaceuticals announced positive results...

RYTM : 56.17 (-2.94%)
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

RYTM : 56.17 (-2.94%)
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

RYTM : 56.17 (-2.94%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

RYTM : 56.17 (-2.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 58.18
2nd Resistance Point 57.58
1st Resistance Point 56.88
Last Price 56.17
1st Support Level 55.58
2nd Support Level 54.98
3rd Support Level 54.28

See More

52-Week High 68.58
Last Price 56.17
Fibonacci 61.8% 55.82
Fibonacci 50% 51.88
Fibonacci 38.2% 47.93
52-Week Low 35.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Trading Volume: The most powerful technical indicator in the world